Yet, despite substantial efforts to design agents that selectively target TP53 mutant AML, including p53 reactivation and inhibition of its negative regulators, most have failed to produce durable clinical benefits (Figure 2D). This evidence concerns the gene TP53 and acute myeloid leukemia.